IGF-1 LR3: a laboratory reagent with no published human studies

IGF-1 LR3 is a modified IGF-1 built to escape the binding proteins that govern how the natural hormone behaves in the body, and it takes its extra potency from exactly that escape [1,2]. Every claim made for it rests on that design, on cell-culture work and on a handful of rodent and guinea-pig experiments from the early 1990s [1,4,5,6]. The only IGF-1 medicine regulators have ever approved is the natural hormone, and it carries a low blood sugar warning serious enough to require monitoring the people who take it [7,8].

What it is

Insulin-like growth factor 1 (IGF-1) is the hormone that carries out much of what growth hormone does. The liver makes most of the IGF-1 in blood, and it acts on nearly every tissue, prompting cells to grow, divide and take up nutrients. It is a close structural relative of insulin, which matters later.

Almost none of the IGF-1 circulating in a person is free. It travels bound to a family of six binding proteins, which control how much reaches tissues and when [2]. Those proteins also stretch its lifespan enormously: free IGF-1 has a half-life of roughly 10 minutes, while IGF-1 in the largest carrier complex lasts 12 to 15 hours [3].

IGF-1 LR3 is an engineered version that was made to escape that control system. Researchers in Adelaide produced it in bacteria as a fusion protein: they replaced the glutamate at position 3 with arginine, and added a 13-amino-acid extension from pig growth hormone at the front [1]. In cell lines that secrete binding proteins, the modified molecule was more potent than natural IGF-1 at stimulating protein and DNA synthesis, even though it binds the IGF-1 receptor itself slightly less well [1]. In cells that make no binding proteins, it was actually weaker than IGF-1 [1]. The extra potency comes entirely from evading the body’s restraint mechanism.

The paper that introduced it says plainly what it was for: analogues that "are very useful reagents in the investigation of IGF-I action" [1]. It is a bench tool, still sold today mainly to keep cells growing in culture.

The animal work

The rodent studies are worth knowing because they are almost always what gets cited for this compound, and they are not what they are made to sound like.

In rats given dexamethasone to induce muscle wasting, IGF-1 delivered by implanted osmotic pump partly reversed the weight loss, and both LR3-IGF-1 and another binding-protein-evading variant were about 2.5 times more potent than natural IGF-1 [4]. In diabetic rats, the same variants were 2.5 to 3 times more potent than IGF-1 at restoring growth, though they failed to correct other insulin-dependent processes [5].

The guinea-pig study is the most instructive. Seven days of continuous LR3-IGF-1 infusion increased the relative weight of the adrenals, gut, kidneys and spleen, but overall body growth was not stimulated, and circulating IGF-1, IGF-2 and binding protein levels fell [6]. Selective organ enlargement without whole-body benefit is not the result the marketing implies.

Every one of these experiments used continuous infusion by pump in an animal, not intermittent injections in a person.

The approved comparison: mecasermin

There is an approved IGF-1 medicine, and looking at it shows what regulators require and what the risks look like when IGF-1 is given to people.

Mecasermin (Increlex) is recombinant human IGF-1, identical to the natural hormone, approved in the US in August 2005 [7]. Its indication is narrow: growth failure in children aged two and over with severe primary IGF-1 deficiency, or with growth hormone gene deletion who have developed antibodies to growth hormone [8]. The label states it is not a substitute for growth hormone in the usual growth hormone indications [8].

The safety section is where the comparison bites. Because IGF-1 has insulin-like effects, low blood sugar is the main hazard. In the clinical studies behind the approval, 71 children treated for an average of 3.9 years, 30 of them (42%) reported hypoglycaemia at least once; five had severe episodes needing assistance, and four had seizures or loss of consciousness [8]. A European registry of 306 patients later found that a prior history of low blood sugar and a diagnosis of Laron syndrome both predicted further episodes [9].

The label also carries warnings about enlarged tonsils and adenoids, raised pressure inside the skull, slipped hip growth plates, scoliosis progression, and reports of malignancies after marketing; it is contraindicated in children with cancer or a history of it [8]. Mecasermin is prescribed with food timing instructions and monitoring precisely because of these issues.

IGF-1 LR3 was engineered to be more potent than the molecule in that label, in a form with no dosing guidance, no monitoring and no supervision.

What sellers claim, and what supports it

The claims attached to IGF-1 LR3 online are muscle growth, faster recovery and repair of tendon or connective tissue. Set against the published record, the picture is this:

Why raised IGF-1 is not automatically good

IGF-1 drives cell division, and there is consistent population evidence linking higher levels to cancer risk. A pooled analysis of individual data from 19 studies, with up to 10,554 prostate cancer cases and 13,618 controls, found men in the top fifth of IGF-1 had about a 29% higher risk of prostate cancer than those in the bottom fifth (odds ratio 1.29, 95% CI 1.16–1.43) [10]. That is an observational association across the normal range, not proof that an injection causes cancer. It is also the main reason IGF-1 is studied cautiously.

What is actually in the vials

Analytical chemists in Cologne examined a black-market injection vial and found it contained Long-R3-IGF-1 with a histidine tag still attached at one end, joined by two linker amino acids [11]. Histidine tags are added during laboratory purification and are normally cleaved off; the authors concluded the material was probably a by-product of biochemical research rather than anything made for injection, and noted that the effects of the tagged protein in humans have never been studied [11].

Why the binding proteins are not a design flaw

The pitch for IGF-1 LR3 treats the binding proteins as an obstacle: they soak up IGF-1, so a version that escapes them should work better. The endocrinology reads the other way round. The binding proteins set how much IGF-1 reaches tissue and when, carry it in reserve, and extend its life in the blood from minutes to hours [2,3]. They are the control system, not friction in it.

The guinea-pig experiment is the closest thing to a test of what happens when that control is bypassed for a week. Some organs grew; the animals did not; and circulating IGF-1, IGF-2 and binding proteins all fell [6]. Whatever one makes of that result, it is not a cleaner version of IGF-1 action. It is a different, less regulated one, measured in an animal.

Legal and regulatory status

• US: IGF-1 LR3 is not an approved drug and has no approved medical use. Mecasermin is the approved IGF-1 product [7].
• UK: not licensed as a medicine.
• Sport: prohibited at all times. The 2026 WADA Prohibited List bans "insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues" under S2.3, growth factors and growth factor modulators [12].

What is still open

Almost everything that matters for a person:

• What a subcutaneous injection of IGF-1 LR3 does to blood sugar, IGF-1 levels or anything else in a human.
• Its half-life and clearance in people.
• Whether the binding-protein-evading design carries a greater risk of low blood sugar than natural IGF-1, which would be the obvious concern.
• What long-term exposure does to tissue growth or cancer risk.
• What is in any given vial, given that at least one analysed product contained a purification tag left over from laboratory use [11].

What this means

Our position is that IGF-1 LR3 has no place in a syringe, and we are not waiting on a trial to say so. The one IGF-1 regulators have ever approved for people is the natural hormone, and it is approved narrowly, dosed with food, and monitored precisely because it drops blood sugar [7,8]. In the studies behind its approval, 30 of 71 children reported hypoglycaemia at least once and four had seizures or lost consciousness [8]. LR3 was engineered to hit harder and last longer than that molecule by escaping the binding proteins that hold natural IGF-1 in reserve [1,2]. Escaping a brake is not a safety feature.

The animal work does not rescue the claim. In the guinea-pig study the compound enlarged organs without growing the animal, and drove circulating IGF-1, IGF-2 and binding protein levels down [6]. That is a different, less governed pattern of IGF-1 activity, measured in an animal, and it is the closest thing anyone has run to a test of what bypassing the control system does.

Set the two alongside each other and the arithmetic is plain. A person injecting IGF-1 LR3 takes on the risk profile of a prescription IGF-1 medicine, low blood sugar first among them, with none of the dosing or monitoring the approved drug requires. They also cannot know what is in the vial: one analysed black-market product was research-grade material with its purification tag still attached [11].

So our read is simple. Read mecasermin’s label if you want to know what IGF-1 does to a human body, because it is the only place anyone has written it down [7,8,9]. Do not inject IGF-1 LR3. The molecule’s selling point and its hazard are the same property, and no trial is needed to see that.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.